摘要
肝内胆管癌(intrahepatic cholangiocarcinoma,ICCA)是起源于肝内胆管上皮的肝脏原发性恶性肿瘤,发病率仅次于肝细胞癌,恶性程度极高,5年总生存率不足10%。手术治疗是其首选的治疗方法,晚期ICCA患者放化疗抵抗,治疗效果不理想,亟需寻找新的有效的治疗方法。随着精准医疗时代的到来,近年来国内外对于ICCA多种驱动基因改变及信号通路异常的机制研究不断深入,靶向治疗和免疫治疗探索已越来越广泛地应用于临床实践。本文拟对ICCA驱动基因改变及靶向治疗的研究进展进行综述。
Intrahepatic cholangiocarcinoma(ICCA)is a primary liver cancer originating from the intrahepatic bile duct epithelium,which is second only to hepatocellular carcinoma in terms of incidence and is extremely malignant with a 5-year overall survival rate of less than 10%.Surgery is the perferred radical treatment choice.Patients with advanced disease are resistant to radiotherapy or chemotherapy,the efficacy is unsatisfactory,and there is an urgent need to find new and effective treatment methods.With the advent of precision medicine,research on the mechanisms of multiple driver gene alterations and signaling pathway abnormalities in intrahepatic cholangiocarcinoma in China and abroad has been intensifying in recent years,and targeted therapy and immunotherapy have been more and more widely used in clinical practice.This paper is intended to review the research progress of driver gene alterations and targeted therapies for intrahepatic cholangiocarcinoma.
作者
张诗汇
李卓
依荷芭丽·迟
石素胜
Zhang Shihui;Li Zhuo;Yihebali·Chi;Shi Susheng(Department of Pathology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100021,China)
出处
《肝癌电子杂志》
2023年第4期15-22,共8页
Electronic Journal of Liver Tumor
基金
国家重点研发计划项目(2021YFF1201300)。
关键词
肝内胆管癌
驱动基因
靶向治疗
Intrahepatic cholangiocarcinoma
Driver genes
Targeted therapies
作者简介
通信作者:石素胜,E-mail:shishusheng@sina.com。
